by Dan Roberts Retinal diseases are not, in themselves, painful. Prolonged ultra-close viewing, however, is often practiced by people with visual impairment. That can cause headaches of the type reported by some members of our low vision community. Generally referred to as eye strain, such discomfort may be caused by stress on the large medial [Read More]
Category: Therapies, Treatments, and Procedures
Anti-VEGF Treatment Should Not Be Expected to Improve Vision
Clearing up a misunderstanding Anti-VEGF drugs for treating wet age-related macular degeneration are highly successful at inhibiting neovascularization, but they are limited to that alone. Clinical trials for Lucentis (ranibizumab) and Eylea (aflibercept) are showing better than 90% success at blocking the growth factors responsible for uncontrolled blood vessel growth into the retina, and off-label [Read More]
Summary of Research and Developments–2017
Presentation to the International Low Vision Support Group June 1, 2017 Dan Roberts INTRODUCTION This is my 12th annual summary of leading research and developments occuring during the past 12 months in the fields of blindness and low vision. Sources for further information will appear beneath each topic heading, but for the sake of brevity, [Read More]
Bright Flash Retinal Photography–a Thing of the Past
by Dan Roberts (Macular Degeneration Support) and Liz Trauernicht (Macular Degeneration Foundation) OCT and nonmydriatic technologies are lessening discomfort and risk of eye exams. MD Support and MD Foundation communicate with thousands of patients who undergo periodic eye exams for diagnosis and treatment of macular degeneration, glaucoma, diabetic retinopathy, and other chronic diseases. Many have [Read More]
Lucentis® Approved for Myopic Macular Degeneration
Genentech has announced FDA approval for Lucentis® as a treatment for patients with choroidal neovascularization (CNV) resulting from myopic macular degeneration (MMD), also known as myopic degeneration. Severe myopia (near-sightedness) can cause uncorrectable central vision impairment, and it may advance to total central vision loss from CNV, which is growth and leakage of blood vessels [Read More]